Marc Hedrick, President & CEO of Plus Therapeutics PSTV, was a guest on Benzinga’s All-Access.
Plus Therapeutics is a clinical-stage pharmaceutical company developing targeted radiotherapeutics with the potential to enhance clinical outcomes in patients with difficult-to-treat cancers of the central nervous system. The company’s technology allows for extremely precise radiotherapeutics.
The company recently presented data at the Society for Neuro-Oncology Conference in San Francisco. Early results from ongoing studies of the company’s lead drug candidate showed extremely promising responses from patients in phase 1.
Watch here:
Featured photo by Hans Reniers on Unsplash.
This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
